Moore Capital Management LP Increases Holdings in IQVIA Holdings Inc. $IQV

Moore Capital Management LP boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 588.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,756 shares of the medical research company’s stock after buying an additional 47,659 shares during the quarter. Moore Capital Management LP’s holdings in IQVIA were worth $10,773,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of IQVIA during the 2nd quarter valued at $2,811,292,000. Geode Capital Management LLC grew its stake in shares of IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after buying an additional 24,453 shares during the last quarter. Boston Partners increased its holdings in shares of IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after acquiring an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in IQVIA by 15.3% during the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after acquiring an additional 367,204 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

Shares of IQV stock opened at $260.48 on Monday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $42.88 billion, a price-to-earnings ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. The business’s fifty day moving average is $222.14 and its 200 day moving average is $189.59. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $265.25.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the firm earned $2.81 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IQV shares. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a report on Thursday, July 9th. BMO Capital Markets boosted their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Robert W. Baird raised their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Finally, Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.